Sponsors (4)
The bill clarifies which orally or self‑administered engineered cyclic peptide drugs enter Medicare price negotiations—likely lowering patient costs and improving program consistency—but raises risks of reduced commercial incentives for peptide R&D and administrative disputes over narrowly defined eligibility.
Patients who take orally, inhaled, or self‑administered engineered cyclic peptide drugs (especially those with chronic conditions and Medicare beneficiaries) will face clearer rules for when those drugs enter Medicare drug‑price negotiation, increasing the chance of lower out‑of‑pocket costs and faster inclusion on negotiation lists.
Medicare and program administrators get clearer statutory language about which novel peptide therapeutics are subject to drug‑price negotiation, improving program consistency and reducing administrative ambiguity for benefit management.
Manufacturers of engineered cyclic peptides (including small biotech firms) may face earlier inclusion in price negotiations and reduced revenue expectations, which could weaken R&D incentives for this modality and slow the future development and availability of new peptide therapies.
The narrow technical definition (e.g., ≤40 amino acids; origin from genetically encoded libraries) could generate disputes over which products qualify, prompting administrative appeals, delays, and uncertainty for hospitals, health systems, and providers managing access.
Based on analysis of 2 sections of legislative text.
Creates a legal definition of “engineered cyclic peptide” for use in federal lists under the Social Security Act and makes a small conforming text change, applying to lists published after enactment.
Adds a new statutory definition of “engineered cyclic peptide” to the Social Security Act’s list-defining provision and makes a small conforming insertion; the definition applies to lists published under that provision on or after the law’s enactment. The change clarifies which orally, inhaled, or self‑administered engineered cyclic peptide products qualify as covered products for programs that rely on that statutory list.
Official title: To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.
Introduced May 15, 2026 by Joseph Morelle · Last progress May 15, 2026